Skip to main navigation

Home
Contact Us

Company
Technology
- RNAi
  - About RNAi Mechanism
  - sd-rxRNA^®
    - RXI-109
    - IncRNA
- Publications
Immuno-Oncology
- RXi’s Immunotherapy Approach
- Immunotherapy of Cancer
Business Development
Clinical Trials
- RXi Clinical Trials
Investors

Investors

Home
Investors
Contact IR

Contact Us

Investor Relations
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

Business Development
James Cardia, Ph.D.
508-929-3634
jcardia@rxipharma.com

Name

Email

Subject

Comments

Investors

News Releases
Events & Presentations
Stock Information
Corporate Governance
Financial Information
Email Alerts
Contact Us

Print Page
Email Page
RSS Feeds
Email Alerts
IR Contact
Share

Contact

Main: 508-767-3861
FAX: 508-767-3862
E-mail: admin@rxipharma.com

Headquarters

257 Simarano Drive
Suite 101
Marlborough, MA 01752

FOLLOW US

RSS
Twitter
Linkedin

Legal

RXi Pharmaceuticals. All rights reserved.